Immunotherapy Series – The Power of Hyperthermia with Surgery
The Power of Hyperthermia with Surgery
The conclusion of currently available research is obvious; surgery causes cancer to spread.    . Did I catch you off guard with this statement? The medical term for the spread of cancer is metastasis. The very treatment, surgery, designed to remove a tumor or to reduce tumor burden to improve survival is the same treatment that can cause cancer to spread. This point is significant because cancer metastasis leads to 90% of the cause of morbidity and mortality in cancer patients  . I will repeat this point time and time because if treatment leads to the metastatic spread of cancer, then that is a treatment that leads to mortality and needs to change. The surgical-induced metastatic spread of cancer is similar to that of full-dose chemotherapy and radiation. The three pillars of conventional medicine cause cancer to spread.
Surgery is a trigger for metastasis:
“…surgery to eliminate the cancer can actually serve to increase the establishment of new metastases and accelerate growth of residual and micrometastatic disease.” 
How can this be possible?
First, no sensationalism; this is not the news. No marketing-based information; this is not marketing. No fear is accepted here either. What I am after is a review and discussion of just the receipts—the evidence. Beyond that, I believe in hope and each individual’s ability to read, interpret and determine the validity of the science on their own, not that found in groupthink. So, here we go.
First and foremost, it is essential to understand that surgery is synonymous with tissue trauma. It is the trauma, recruitment of the healing process, and the resultant disruption of the healing process that promotes the metastatic spread of cancer. It is within the tumor microenvironment of cancer that the high jack of the normal healing process occurs. It is here that the healing process serves the benefit and survival of cancer at the detriment of the body. This is not new information. This concept was first described over 100 years ago, near the turn of the 20th century! 
How does surgery cause the metastatic spread of cancer?
First, the information is not new; the detailed description of how surgery causes the metastatic spread of cancer is widely known. This process is not a theory but is a scientific fact that is confirmed time and time again.
A lot of the negative impacts from surgery are within the immune system. It is important to understand that surgery suppresses the immune system 2      . Surgery suppresses natural killer (NK) cell and macrophage activity  . The degree of immune suppression correlates with the volume of surgery and the risk of tumor regrowth. This evidence should require a review and analysis of the massive surgery volume, including debulking, often used in surgery. Is surgery providing a brief reprieve, only to set the stage for massive expansion?
Immunosuppression is a normal part of the post-operative period. In cancer, immunosuppression in the post-operative period is critically important. The surgical induced immunosuppression is a natural occurrence and is beyond any deliberate immune suppression drugs that can be and are often used in the post-operative state. Take organ transplant surgery for example, immune suppression is a mainstay and necessary component of treatment. Second, opiates are the conventional primary treatment option for pain control in the post-operative period. These opiates are often scheduled whether or not there is pain. In addition, in case you haven’t heard, there is something called a prescription opiate addiction epidemic? Opiates double-down on immunosuppression    . With the effective use of medical marijuana for pain control, there is less need for the use of opiates. In the post-operative period, opiate use, in addition to the immunosuppression from the surgery itself, is like throwing gasoline on the fire of cancer. Unfortunately, in both cases, physicians are the means of delivery. This statement is not easy to make. In my former physician life (wink, wink), I was a surgeon.
Beyond the generalized immunosuppression and general opiate use, surgery causes the metastatic spread of cancer in a clearly defined series of sequences 7:
- increase in inflammatory signaling (NF-kappaB, IL-1, IL-6, TNF-α…)
- increases stress response (cortisol, epinephrine, and norepinephrine)
- changes the tumor microenvironment
- accelerates growth
- increase in invasion
- increase tumor shedding in the blood
- increase tumor shedding in the lymphatics
- increase in circulating tumor cells (CTCs)
- increase in CTC migration
- increase in CTC survival
- increase in immune system invasion
- increase dissemination of cancer cells
- metastatic site preparation
- increase adherence of CTCs at new, potential metastatic sites
- formation of new micrometastasis
- changes the new micrometastatic microenvironment
- accelerated growth of micrometastasis
- increase invasion at metastatic sites
- increase in treatment resistance
This sequencing of the metastatic spread of cancer, as a result of surgery, also causes the increase in local recurrence. This sequencing of the metastatic spread of cancer, resulting from surgery, also causes an increase in local recurrence. Local recurrence and metastasis are just the same processes; the only difference is the location. One spreads to distant sites, and the other is just a return to the scene of the crime. The more surgery undertaken, major versus minor surgery, open versus laparoscopy surgery, results in a decrease in survival .
Hyperthermia protects against surgical-induced metastasis.
With the cut first and ask questions later surgical approach to conventional cancer treatment, it is important to find ways to prevent surgically induced immunosuppression that aids the process of metastasis. Hyperthermia to the rescue again. A paper published in Critical Reviews in Hematology/Oncology in 2016 showed that hyperthermia counters the surgically induced immunosuppression and actually strengthens the immune system in the critical postoperative period . Another study published in the International Journal of Colorectal Disease showed that hyperthermia, in conjunction with chemotherapy and radiation, prevented local recurrence in patients that had undergone surgical resection for rectal cancer . An excellent question to consider here, is the addition of chemotherapy and radiation even required? It is known that full-dose chemotherapy    and radiation   , each individually, lead to the metastatic spread of cancer. Can hyperthermia do the work alone? The 2016 study highlighted above suggests this might be so.
How about we take this a step deeper? A recent study in the International Journal of Hyperthermia published in 2019 shows that hyperthermia can reduce local recurrence at the time of surgery . In this study of 63 people with metastatic brain cancer, 10 out of the 63 developed local recurrence after surgical resection. That equates to a 15.8% local recurrence rate. That sounds pretty good on its face. But, when you compare it to the current 34% receiving conventional standard of care treatment, it looks really good. Overall, that is a 55% reduction of local recurrence as a result of the addition of hyperthermia to surgery. That is the evidence of the power of hyperthermia to reduce local recurrence. The same could be said to apply to metastasis because the same steps and processes, outlined above, are involved.
Cancer is a systemic process from day one  . This favors whole body hyperthermia over local hyperthermia in the treatment of cancer. The abscopal effect , which is treatment that results in tumor regression at distant tumor sites, is lauded by local hyperthermia advocates as the means to achieve systemic effects from local hyperthermia. In reality, the abscopal effect is quite rare, limited, and anecdotal 27 33. The current dogma of viewing cancer through a linear, sequential process is overly simplistic and very flawed. The sequence I highlighted above is dynamic, not linear. It is more on the level and thinking of quantum physics—it is all happening at once. In this light, hyperthermia is working systemically, yet dynamically, to augment the immune system in an anti-tumor fashion. Hyperthermia increases NK cell number, function, and cytotoxicity   , increases dendritic cell activation, crosstalk, and antigen presentation to other immune cells  , and increases cytotoxic T lymphocyte number, targeting, and function  . As so often is the case, timing, temperature (dose), and duration are critical to these effects. The overall result is a systemic increase in anti-cancer immune activation.
We are not opposed to surgery, far from it. Heck, I was a surgeon myself. Dr. Lodi and I would just rather avoid it if all possible. Just look at the evidence I reviewed, and one can see why we should not rush to cut. When indicated, when a large volume of disease exists, surgery can significantly impact tumor burden reduction or preserve vital organ function when threatened by tumor growth. That being said, every time a tumor is handled, or surgical intervention ensues, circulating tumor cells increase by at least ten times . My experience is that when ten fold is quoted, the reality is actually magnitudes higher. Just because we can cut doesn’t mean we should cut. Once cutting begins, there is no going back. We can only help to limit the damage. Fortunately, hyperthermia, and other integrative, holistic therapies, can limit the collateral damage called metastasis that can result from surgery.
 Qadri SS, Wang JH, Coffey JC, Alam M, O’Donnell A, Aherne T, Redmond HP. Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition. Ann Thorac Surg. 2005 Mar;79(3):990-5; discussion 990-5. doi: 10.1016/j.athoracsur.2004.07.042.
 Tai LH, Tanese de Souza C, Bélanger S, Ly L, Alkayyal AA, Zhang J, Rintoul JL, Ananth AA, Lam T, Breitbach CJ, Falls TJ, Kirin DH, Bell JC, Makrigiannis AP, Ayer RA. Preventing Postoperative Metastatic Disease by Inhibiting Surgery-Induced Dysfunction in Natural Killer Cells. Cancer Res. Jan 2013;73(1):97-107; DOI: 10.1158/0008-5472.CAN-12-1993
 Angka L, Khan ST, Kilgour MK, Xu R, Kennedy MA, Auer RC. Dysfunctional Natural Killer Cells in the Aftermath of Cancer Surgery. International Journal of Molecular Sciences. 2017;18(8):1787. https://doi.org/10.3390/ijms18081787
 Tsuchiya Y, Sawada S, Yoshioka I, Ohashi Y, Matsuo M, Harimaya Y, Tsukada K, Saiki I. Increased surgical stress promotes tumor metastasis. Surgery. 2003;133:547-55.
 Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679‐695.
 Dillekås H, Demicheli R, Ardoino I, Jensen SA, Biganzoli E, Straume O. The recurrence pattern following delayed breast reconstruction after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases. Breast Cancer Res Treat. 2016;158(1):169‐178.
 Tohme S, Simmons RL, Tsung A. Surgery for Cancer: A Trigger for Metastases. Cancer Res. 2017;77(7):1548-1552. doi:10.1158/0008-5472.CAN-16-1536
 Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID. The effects of surgery on tumor growth: a century of investigations. Ann Oncol. Nov 2008;19(11):1821-8. doi: 10.1093/annonc/mdn386.
 Bakos O, Lawson C, Rouleau S et al. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J Immunotherapy Cancer. 2018;6(86). https://doi.org/10.1186/s40425-018-0398-7
 Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M. Immunosuppression following surgical and traumatic injury. Surg Today. 2010;40:793-808.
 Ananth A, Tai L, Lansdell C, Alkayyal A, Baxter K, Angka L, et al. Surgical stress abrogates pre-existing protective T cell mediated anti-tumor immunity leading to postoperative Cancer recurrence. PLoS One. 2016;11:1–19.
 Rosenne E, Sorski L, Shaashua L, Neeman E, Matzner P, Levi B, et al. In vivo suppression of NK cell cytotoxicity by stress and surgery: glucocorticoids have a minor role compared to catecholamines and prostaglandins. Brain Behav Immun. 2014;37:207–19.
 Yakar I, Melamed R, Shakhar G, Shakhar K, Rosenne E, Abudarham N, et al. Prostaglandin E 2 suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Ann Surg Oncol. 2003;10:469–79.
 Greenfeld K, Avraham R, Benish M, Goldfarb Y, Rosenne E, Shapira Y, et al. Immune suppression while awaiting surgery and following it: dissociations between plasma cytokine levels, their induced production, and NK cell cytotoxicity. Brain Behav Immun. 2007;21:503–13.
 Rushfeldt C, Sveinbjornsson B, Seljelid R, Smedsrod B. Early events of hepatic metastasis formation in mice: role of Kupffer and NK-cells in natural and interferon-gamma-stimulated defense. The Journal of surgical research. Apr 1999;82(2):209–215.
 Oosterling SJ, van der Bij GJ, Meijer GA, Tuk CW, van Garderen E, van Rooijen N, et al. Macrophages direct tumour histology and clinical outcome in a colon cancer model. The Journal of pathology. Oct 2005;207(2):147–155.
 Vallejo R, de Leon-Casasola O, Ramsun B. Opioid Therapy and Immunosuppression: A Review. American Journal of Therapeutics. September-October 2004;11(5):354-365. doi: 10.1097/01.mjt.0000132250.95650.85
 Sacerdote P, Bianchi M, Gaspani L, Manfredi B, Maucione A, Terno G, Ammatuna M, Panerai AE. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg 2000;90:1411-4.
 Sacerdote P. Opioids and the immune system. Palliat Med. 2006;20 Suppl 1:s9-15. PMID: 16764216.
 Koodie L., Roy S. (2013) Morphine and Immunosuppression in the Context of Tumor Growth and Metastasis. In: Parat MO. (eds) Morphine and Metastasis. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5678-6_3
 Coffey JC, Smith MJ, Wang JH, Bouchier-Hayes D, Cotter TG, Redmond HP. Cancer surgery: risks and opportunities. BioEssays : news and reviews in molecular, cellular and developmental biology. Apr 2006;28(4):433–437.
 Mallory M, Gogineni E, Jones GC, Greer L, Simone CB, 2nd. Therapeutic hyperthermia: The old, the new, and the upcoming. Crit Rev Oncol Hematol. 2016;97:56-64.
 Korenaga D, Matsushima T, Adachi Y, Mori M, Matsuda H, Kuwano H, Sugimachi K. Preoperative hyperthermia combined with chemotherapy and radiotherapy for patients with rectal carcinoma may prevent early local pelvic recurrence. Int J Colorectal Dis. Dec 1992;7(4):206-9. doi: 10.1007/BF00341222.
 Filippou PS, Karagiannis GS. Cytokine storm during chemotherapy: a new companion diagnostic emerges?. Oncotarget. 2020;11(3):213-215. doi:10.18632/oncotarget.27442
 Karagiannis GS, Condeelis JS, Oktay MH. Chemotherapy-induced metastasis: mechanisms and translational opportunities. Clin Exp Metastasis. 2018;35(4):269-284. doi:10.1007/s10585-017-9870-x
 Karagiannis GS, Condeelis JS, Oktay MH. Chemotherapy-Induced Metastasis: Molecular Mechanisms, Clinical Manifestations, Therapeutic Interventions. Cancer Res. 2019;79(18):4567-4576. doi:10.1158/0008-5472.CAN-19-1147
 Vilalta M, Rafat M, Graves EE. Effects of radiation on metastasis and tumor cell migration. Cell Mol Life Sci. 2016;73(16):2999-3007. doi:10.1007/s00018-016-2210-5
 Li D, Qu C, Ning Z, et al. Radiation promotes epithelial-to-mesenchymal transition and invasion of pancreatic cancer cell by activating carcinoma-associated fibroblasts. Am J Cancer Res. 2016;6(10):2192-2206. Published 2016 Oct 1.
 Lee SY, Jeong EK, Ju MK, et al. Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol Cancer. 2017;16(1):10. Published 2017 Jan 30. doi:10.1186/s12943-016-0577-4
 Byun YH, Gwak HS, Kwon J, Song MK, Shin SH, Jo YH, Yoo H, Lee SH. Local recurrence of brain metastasis reduced by intra-operative hyperthermia treatment, International Journal of Hyperthermia. 2018;35:1:168-175. DOI: 10.1080/02656736.2018.1488004
 Redig AJ & McAllister SS Breast cancer as a systemic disease: a view of metastasis. J. Intern. Med. 2013;274:113–126.
 Zajicek G Cancer as a systemic disease. Med. Hypotheses. 1978;4:193–207.
 Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41(6):503-510. doi:10.1016/j.ctrv.2015.03.011
 Farjadian S, Norouzian M, Younesi V, Ebrahimpour A, Lotfi R. Hyperthermia increases natural killer cell cytotoxicity against SW-872 liposarcoma cell line. Iran J Immunol. Jun 2013;10(2):93-102
 Terunuma H, Deng X, Toki A, Yoshimura A, Nishino N, Takano Y, Nieda M, Sasanuma JI, Teranishi Y, Watanabe K. Effects of Hyperthermia on the Host Immune System: From NK Cell-based Science to Clinical Application. Thermal Medicine. 2012;28(1):1-9.
 Kappel M, Stadeager C, Tvede N, Galbo H, Pedersen BK. Effects of in vivo hyperthermia on natural killer cell activity, in vitro proliferative responses and blood mononuclear cell subpopulations. Clin Exp Immunol. 1991;84(1):175-180. doi:10.1111/j.1365-2249.1991.tb08144.x
 Ostberg JR, Patel R, Repasky EA. Regulation of immune activity by mild (fever-range) whole body hyperthermia: Effects on epidermal Langerhans cells. Cell Stress Chaperones 2000; 5: 458–461
 Frey B, Weiss EM, Rubner Y, Wunderlich R, Ott OJ, Sauer R, Fietkau R, Gaipl US. Old and new facts about hyperthermia-induced modulations of the immune system, International Journal of Hyperthermia. 2012;28:6:528-542, DOI: 10.3109/02656736.2012.677933
 MacDonald HR. Effect of hyperthermia on the functional activity of cytotoxic T-lymphocytes. J Natl Cancer Inst. Oct 1977;59(4):1263-8. doi: 10.1093/jnci/59.4.1263.
 Dieing A, Ahlers O, Hildebrandt B, Kerner T, Tamm I, Possinger K, Wust P. The effect of induced hyperthermia on the immune system. Prog Brain Res. 2007;162:137-52. doi: 10.1016/S0079-6123(06)62008-6.
 Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer research. May 1974;34(5):997–1004.
For more articles like, “Immunotherapy Series – The Power of Hyperthermia with Surgery” visit our blog.
Dr. Nathan Goodyear is dedicated to disease prevention, disease resolution, and the Wellness Lifestyle through a solution-based, Integrative Medicine approach founded in science. Dr. Goodyear received his Bachelor of Arts from Louisiana Tech University and his Doctor of Medicine from LSU Health Sciences Center.
He is Board Certified in Obstetrics and Gynecology and served as the Chief Resident in Obstetrics and Gynecology at the University of Tennessee. Dr. Goodyear has practiced Integrative Medicine since 2006. Dr. Goodyear is a Fellow in Functional and Regenerative Medicine and served on the board of the American Functional Medicine Association. Dr Goodyear is licensed by the Arizona Homeopathic and Integrative Medical Board in the State of Arizona. Dr. Goodyear is a published author, Man Boob Nation–an Integrative medicine approach to low Testosterone published in 2014, and Total Testosterone Transformation published in 2017